therapeutic antibody development
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
This is the first treatment breakthrough in pulmonary fibrosis in over a decade
Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim
The collaboration began in 2013 and was later expanded in 2020 and 2023
Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases
The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline
HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category
Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....
Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education
See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
VuuAI and Amiculum partner to transform content engagement in pharma
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation platform. The collaboration is designed to optimize the deployment of...
Does real-world use of AI in systematic literature reviews result in time and cost savings?
By Manca Povsic and Emma Griffiths
Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m
The deal focuses on T cell-based therapies for autoimmune disease